LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

LLY

1,010.53

-2.15%↓

JNJ

202.19

-1.57%↓

ABBV

228.68

-0.7%↓

UNH

333.72

-1.99%↓

AZN

89.97

-0.96%↓

Начало・Списък с акции・Voyager Therapeutics Inc

Voyager Therapeutics Inc

Затворен

4.34 2.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.13

Максимум

4.43

Ключови измерители
By Trading Economics
Приходи	5.5M -28M
Продажби	8.2M 13M
EPS	-0.47
Марж на печалбата	-208.694
Служители	172
EBITDA	8.7M -27M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+271.35% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-35M 220M
Предишно отваряне	1.5
Предишно затваряне	4.34

Техническа оценка

By Trading Central

Увереност

Bearish Evidence

3.17 / 3.4644 Подкрепа & съпротива

Voyager Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.12.2025 г., 20:41 ч. UTC

Печалби

Значими двигатели на пазара

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4.12.2025 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4.12.2025 г., 17:43 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4.12.2025 г., 17:01 ч. UTC

Печалби

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4.12.2025 г., 23:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

4.12.2025 г., 21:54 ч. UTC

Пазарно говорене

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

4.12.2025 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 21:48 ч. UTC

Пазарно говорене

Scales Hits Mark With Earnings Guidance -- Market Talk

4.12.2025 г., 21:37 ч. UTC

Печалби

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4.12.2025 г., 21:36 ч. UTC

Печалби

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

4.12.2025 г., 20:15 ч. UTC

Пазарно говорене

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4.12.2025 г., 20:04 ч. UTC

Пазарно говорене

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4.12.2025 г., 19:54 ч. UTC

Пазарно говорене

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4.12.2025 г., 19:44 ч. UTC

Придобивния, сливания и поглъщания

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4.12.2025 г., 19:33 ч. UTC

Пазарно говорене

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4.12.2025 г., 19:01 ч. UTC

Придобивния, сливания и поглъщания

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4.12.2025 г., 18:58 ч. UTC

Пазарно говорене

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4.12.2025 г., 17:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

4.12.2025 г., 17:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

4.12.2025 г., 16:41 ч. UTC

Пазарно говорене

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4.12.2025 г., 16:33 ч. UTC

Пазарно говорене

Печалби

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Voyager Therapeutics Inc Прогноза

Ценова цел

By TipRanks

271.35% нагоре

12-месечна прогноза

Среден 14 USD 271.35%

Висок 25 USD

Нисък 8 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Voyager Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Voyager Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

3.17 / 3.4644Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Voyager Therapeutics Inc

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.